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Abstract
Background: HIV-associated neurocognitive disorders (HANDs) afflict more than half of HIV-1-positive individuals.
The transactivator of transcription (Tat) produced by HIV virus elicits inflammatory process and is a major neurotoxic
mediator that induce neuron damage during HAND pathogenesis. Activated astrocytes are important cells involved
in neuroinflammation and neuronal damage. Purinergic receptors expressed in astrocytes participate in a positive
feedback loop in virus-induced neurotoxicity. Here, we investigated that whether P2Y4R, a P2Y receptor subtype,
that expressed in astrocyte participates in Tat-induced neuronal death in vitro and in vivo.
Methods: Soluble Tat protein was performed to determine the expression of P2Y4R and proinflammatory cytokines
in astrocytes using siRNA technique via real-time PCR, Western blot, and immunofluorescence assays. Cytometric
bead array was used to measure proinflammatory cytokine release. The TUNEL staining and MTT cell viability assay
were analyzed for HT22 cell apoptosis and viability, and the ApopTag® peroxidase in situ apoptosis detection kit
and cresyl violet staining for apoptosis and death of hippocampal neuron in vivo.
Results: We found that Tat challenge increased the expression of P2Y4R in astrocytes. P2Y4R signaling in astrocytes
was involved in Tat-induced inflammatory cytokine production via PI3K/Akt- and ERK1/2-dependent pathways.
Knockdown of P2Y4R expression significantly reduced inflammatory cytokine production and relieved Tat-mediated
neuronal apoptosis in vitro. Furthermore, in vivo challenged with Tat, P2Y4R knockdown mice showed decreased
inflammation and neuronal damage, especially in hippocampal CA1 region.
Conclusions: Our data provide novel insights into astrocyte-mediated neuron damage during HIV-1 infection and
suggest a potential therapeutic target for HANDs.
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Background
HIV-associated neurocognitive disorders (HAND) include
asymptomatic neurocognitive impairment (ANI), mild neu-
rocognitive disorder (MND), and HIV-associated dementia.
Although highly active antiretroviral therapy (HAART) re-
duced viral loading and prolonged life-span of acquired im-
munodeficiency syndrome (AIDS) patients, the prevalence
of HAND appears to be rising up to more than 50% among
human immunodeficiency virus type 1 (HIV-1)-positive
individuals. HAND is characterized by degenerative damage
and loss of neurons and ultimately develops into
HIV-associated dementia (HAD) [1–4]. In the central ner-
vous system (CNS), HIV-1 itself and HIV-1-encoded pro-
teins including transactivator of transcription (Tat) enhance
altered neuroinflammation and neurotoxicity in astrocytes
and microglia, contributing to the neuron damage and loss
in the process of HAND [5–8].
Reactive astrocytosis is an important feature in inflam-
matory environment during the pathology of HAND [5,
9, 10]. Astrocytes, the major glial cell type within the
brain [11, 12], represent an important reservoir for the
production of various mediators of inflammation, par-
ticularly in response to HIV-1 infection [13, 14]. Astro-
cytes support neuron function through promoting
synaptic formation and plasticity, and architecture the
formation of the blood-brain barrier (BBB) [10]. Add-
itionally, activated astrocytes are able to interact with
the peripheral immune system by recruiting leukocytes
and monocytes into the CNS [15]. Meanwhile, astrocyte
activation is associated with the pathogenesis of HAND
characterized by an increased the production of
pro-inflammatory cytokines and chemokines [3, 5]. In re-
sponse to HIV-1 or Tat, astrocytes elicit chemokines and
chemokine production to promote the recruitment of T
cells and monocytes into the brain [5]. HIV-infected
monocytes and T cells not only infect brain resident cells
but also release proinflammatory cytokines such as tumor
necrosis factor (TNF) and interleukin-1 beta (IL-1β),
which further activates astrocytes [5]. Of important, these
activated astrocytes are important contributors to neuro-
inflammation and release neurotoxic factors such as exci-
tatory amino acids and adenosine 5′-triphosphate (ATP),
resulting in neuronal dysfunction and death [16, 17].
Tat, a multifunctional protein of 86-101 aa, is produced
from HIV-1-infected cells and releases into the tissues and
blood in HIV-1+ individuals. Meanwhile, Tat is secreted
from resident CNS cells such as microglia and astrocytes
into the CSF [18], and increases the production of soluble
neurotoxic factors including inflammatory cytokines [5],
which involved in the development and progression of
HAND in HIV-1+ patients [19–24]. Studies showed that
Tat induced pro-inflammatory cytokines like interleukin-6
(IL-6), IL-8, and interferon-gamma-inducible 10-Kd protein
(IP-10) in astrocytes, which involved nuclear factor-kappa B
(NF-κB), AP-1, C/EBPα, and C/EBPγ transcription factors
and JAK, PI3K/Akt, and MAPK signaling pathways [25–
27]. In addition, some studies reported that Tat induced
neurotoxic factors such as excitatory amino acids, ATP, and
calcium overload, resulting in neuron death [28, 29]. There-
fore, Tat protein treatment in mice can induce key aspects
of HAND neurotoxicity [30].
Purinergic P2 receptor family includes P2Y1R, P2Y2R,
P2Y4R, P2Y6R, P2Y12R, and P2Y14R that express in CNS
astrocytes [31, 32]. Recent data have demonstrated that
ATP is recognized to act through purinergic P2 receptors
widely expressed in the brain [33], which are involved in
glia-glia and glia-neuron communications [34], thus playing
important physiological and pathophysiological roles in a
variety of biological processes and neurodegenerative dis-
eases [35]. Previous evidence has documented that a
non-selective P2 receptor antagonist, PPADS, improves the
morphological and functional alterations provoked by the
ischemic injury [36]; A P2Y1 agonist, 2-MeSADP, signifi-
cantly reduces cytotoxic edema and the magnitude of ische-
mic lesions [37]. Inhibition of P2Y1 receptors in astrocytes
results in cytokine/chemokine transcriptional suppression,
which involves the NF-kB pathway [38]. Moreover, PPADS
confers neuroprotection against glutamate/NMDA toxicity
[39]. Recent studies found that purinergic receptor P2Y6
contributes to 1-methyl-4-phenylpyridinium-induced oxi-
dative stress and cell death [40]. PI3K/AKT and ERK
MAPK pathways are involved in activating purinergic P2
receptor [41–43]. These results prompt us to determine
purinergic P2 receptor signaling in astrocytes and their
roles in HAND pathogenesis.
In the present study, we analyzed purinergic P2 recep-
tor expression in astrocytes treated by soluble Tat pro-
tein. Our results found that Tat enhanced P2Y4R
signaling to mediate inflammatory process that contrib-
uted to neuron apoptosis and death via PI3K/AKT- and
ERK-dependent pathways. Furthermore, P2Y4R knock-
down in mice significantly suppressed inflammatory
cytokine production and relieved hippocampal CA1
neuron apoptosis in Tat-treated mice. These data sup-
port a role of P2Y4R in regulating neuroinflammation
and neuron damage during the process of HAND.
Methods
Animals
C57BL/6 mice were purchased from Nanjing University
Laboratory Animal Center. Mice were bred and main-
tained under specific pathogen-free conditions. All ex-
perimental procedures described in our study were
carried out based on the Provision and General Recom-
mendation of the Chinese Laboratory Association. The
protocol was approved by the Institutional Animal Care
and Use Committee of Xuzhou Medical University.
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Reagents and antibodies
Full-length recombinant Tat (1-101 aa, ab83353) was
from Abcam. ATP (A1852), LY294002 (440202), and
PD98059 (P215) were from Sigma-Aldrich. Multiplex
magnetic bead-based antibody detection kits (cytokine
and chemokine detection kits, Cytometric Bead Array)
were purchased from BD Biosciences (560485, 558342).
LV3-sh-NC and LV3-sh-mouse P2Y4R were purchased
from GenePharma (Shanghai, China). TUNEL staining kit
(11684817910) was from Roche. The ApopTag® peroxidase
in situ apoptosis detection kit (S7100) was purchased from
Chemicon International, Inc. Anti-GFAP antibodies
(ab4648 and MAB360) were from Abcam and Millipore.
Anti-P2Y4R antibody (APR-006) was from Alomone labs.
Anti-p-AKT (Ser473, 4060) and anti-p-ERK1/2 (Thr202/
Thr204, 5726) antibodies were from Cell Signaling Biotech-
nology. Anti-Bcl-2 (sc-509) antibody, anti-Bax (sc-20067)
antibody, anti-β-Actin (sc-47778), and anti-Tubulin anti-
bodies were purchased from Santa Cruz Biotechnology.
Alexa Fluor® 488 donkey anti-mouse IgG (A21202) and
Alexa Fluor® 594 donkey anti-mouse IgG (A21207) anti-
bodies were from Life technologies. The secondary anti-
bodies of goat anti-mouse IgG and goat anti-rabbit IgG
were purchased from Santa Cruz Biotechnology.
Cell culture
Isolation and culture of primary mouse astrocytes
from 0- to 1-day-old C57BL/6 mice were established
as previously described [44–46]. Briefly, the cerebral
cortices freed of meninges were dissected, minced,
and digested. The cells were filtrated, transferred to
culture flasks pre-coated with 1 mg/ml poly-L-lysine
(Sigma-Aldrich), and then cultured DMEM/F12
medium containing 10% fetal bovine serum (FBS).
Cells were passed for three passages, and then de-
tected glial fibrillary acidic protein (GFAP, astrocytic
marker) expression through immunofluorescence as-
says (IFA). Finally, at least 95% GAFP+ cells were
used to research.
Murine hippocampal neuron HT-22 cells and hu-
man glioma U261 cells were obtained from the Cell
Bank of Chinese Academy of Science (Shanghai,
China). HT-22 and U261 cells were cultured in
DMEM supplemented with 10% heat-inactivated FBS
(fetal bovine serum), 50 U/ml penicillin and strepto-
mycin (Sigma-Aldrich) under a humidified atmos-
phere containing 5% CO2 at 37 °C.
RNA extraction, reverse transcription, and real-time PCR
assay
Total RNA was extracted from astrocytes and hippocam-
pal tissues according to manufactures instructions. Re-
verse transcription and real-time PCR (qPCR) assay was
performed as previously described [47]. The sequences of
primers are listed in Additional file 1: Table S1.
Western blotting analysis
Total protein was extracted from mouse hippocampal
tissues and from primary astrocytes as described previ-
ously [48]. The expression of protein in samples was
normalized by β-actin or Tubulin.
Immunofluorescence assay
Protein expression was performed by the immunofluor-
escence assay (IFA) as previously described [49].
Cytometric bead array
The concentration of inflammatory cytokines was mea-
sured using a cytometric bead array (CBA; Multiplex
magnetic bead-based antibody detection kits, BD Biosci-
ences, CA, USA) as per manufacturer’s instructions.
Conditioned media samples from astrocytes were spun
at 160×g for 5 min and collected and stored at − 20 °C.
CBA samples were run on a FACSCanto™ II flow cyt-
ometer (BD Biosciences, CA, USA). Data were analyzed
using the BD FACSDiva software and normalized as de-
scribed previously [46, 50].
MTT cell viability assay
Cell viability was examined by MTT assays according to
standard methods as previously described [48].
ATP measurement
ATP levels were measured using the ATPlite lumines-
cence assay system (PerkinElmer, 6016943) according to
the manufacturer’s instructions [51].
Lentivirus and Tat administration in mice
To silence the mouse P2Y4R, shRNA sequences were
designed. ShRNA sequences were as followed:
sh-negative control, 5′-TTC TCC GAA CGT GTC ACG
T-3′; sh-P2Y4R-1, 5′-CCU GUU GCC UCU GAG CUA
UTT-3′ and sh-P2Y4R-2, 5′-CCA CUU ACA UGU
UCC AUU UTT-3′; sh-P2Y4R-3, 5′-CCT GTT GCC
TCT GAG CAT T-3′. ShRNA sequences were cloned
into the LV3-eGFP vector (GenePharma), and lentivi-
ruses were packaged, which were named as LV-sh-Ctrl,
LV-sh-P2Y4R1/2/3, respectively.
Then, 1 × 107 TU (transduction unit) of LV-sh-Ctrl
or LV-sh-P2Y4R were injected into 8-week-old
C57BL/6 mice through the tail vein (Additional file 1:
Figure S1), followed by Tat protein (1 μg) in 2 μl of
PBS was administrated to mice through intracerebro-
ventricular (i.c.v.) infusion site at A/P 1.0 mm, L/M
1.0 mm, and D/V 3.0 mm from the bregma, two
times per week for 4 weeks
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Histopathology
Mice were anesthetized and perfusion-fixed with 4%
paraformaldehyde. For measuring hippocampal neuron
apoptosis, sections (4 μm) from brain tissues were deter-
mined by the ApopTag® peroxidase in situ apoptosis de-
tection kit according to the manufacturer’s protocol as
previously described [52]. For evaluating hippocampal
neuron death, the paraffin-embedded sections (4 μm)
from brain tissues were stained with cresyl violet and ex-
amined by light microscopy, and the pyramidal cell
numbers of surviving in hippocampal CA1/1 mm of
length were counted as neuron density [52].
Statistical analysis
Statistical analysis was performed using SPSS version
18.0 to analyze experimental data. Data presented as
mean ± standard error of mean (mean ± S.E.M.). Statis-
tical significance was determined by the two-tailed Stu-
dent’s t test or one-way analysis of variance (ANOVA).
P < 0.05 was considered significant.
Results
HIV-1 Tat promotes P2Y4R expression in primary mouse
astrocytes
To test whether purinergic P2Y receptors involve in
Tat-induced astrocyte activation, we first determined
P2YR expression after Tat stimulation. Primary mouse as-
trocytes were treated with 100 ng/ml of soluble full-length
recombinant Tat protein in serum-free media; q-PCR
assay were performed to measure the transcriptional levels
of P2Y1R, P2Y2R, P2Y4R, P2Y6R, P2Y12R, and P2Y14R.
As shown in Fig. 1a, the mRNA expression level of P2Y4R
was dramatically increased starting at 3 h, peaked at 12 h,
and remained high even after 24 h Tat stimulation. Besides
P2Y2R mRNA level elevated only at 6 h, the levels of ex-
pression of other P2Y receptors were not changed. To de-
termine whether Tat promoted P2Y4R protein expression,
immunoblotting and IFA were carried out. Western blot-
ting results indicated that Tat induced P2Y4R expression
(Fig. 1b, c), which was correlated with its mRNA expres-
sion. Moreover, IFA showed that P2Y4R expression was
higher in Tat-treated astrocytes than that of negative
Fig. 1 Tat upregulated P2Y4R expression in mouse astrocytes. Primary mouse astrocytes were incubated in a serum-free medium overnight followed
by treating with soluble Tat protein for various time points. a Representative mRNA levels of P2Y receptors were measured by qPCR assay. These data
are from three independent experiments. The relative expression levels of genes were normalized to the expression of mouse Actin. NC negative
control. b Representative protein expression of P2Y4R in mouse primary astrocytes was detected by Western blotting assay. c Quantification of P2Y4R
protein level. Numbers under the bands were the relative intensity of the bands after calculating for loading control using β-actin. The relative value of
proteins in NC group was considered as “1”; same for all of following Western blotting Figures. Error bars represent the mean ± S.E.M. These data are
from three independent experiments. **P < 0.01 and ***P < 0.001 versus NC group. d Immunofluorescent assay for GFAP (green) and P2Y4R (red) in
primary mouse astrocytes. Scale bars, 50 μm. iTat inactivated Tat, NC negative group. e Western blotting assay verified protein expression of P2Y4R was
in mouse primary astrocytes treated with Tat or iTat for 6 h. The data are from three independent experiments. f qPCR assay and g Western blotting
assay were performed to assess the expression of GFAP mRNA and protein. The relative expression levels of genes were normalized to the expression
of mouse Actin. Error bars represent the mean ± S.E.M. The data are from three independent experiments. *P < 0.05 versus NC group
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control (NC) group (Fig. 1d). To rule out Tat-unrelated ef-
fect, we heat-inactivated Tat (iTat) by incubating the re-
combinant Tat protein in 95 °C for 10 min before adding
to primary astrocyte culture. IFA and Western blotting
assay indicated that iTat could no longer induce P2Y4R
expression (Fig. 1d, e). These results suggest that Tat en-
hances P2Y4R expression in astrocytes.
Multiple reports have suggested that HIV-1 Tat in-
duces GFAP expression in astrocytes as a marker for
tat-induced astrogliosis. As shown in Fig. 1d, Tat ap-
peared to increase GFAP expression. To determine the
role of GFAP induction by Tat, q-PCR and immunoblot
assay were performed. The soluble Tat enhanced the
level of GFAP mRNA and protein (Fig. 1f, g).
Fig. 2 PI3K/Akt and ERK signal pathways were involved in Tat-induced P2Y4R expression and inflammatory response in mouse astrocytes. a
Primary mouse astrocytes were incubated in a serum-free medium overnight followed by treating with soluble Tat protein for different time
point. Representative levels of phosphorylation of Akt (p-Akt) and p-ERK1/2 were displayed by Western blotting assay. These data are from three
independent experiments. b, c Primary mouse astrocytes were incubated in a serum-free medium overnight followed by pretreating with or
without PI3K pathway inhibitor LY294002 (10 μM) and ERK1/2 pathway inhibitor PD98059 (50 μM) for 2 h, respectively, prior to soluble Tat
protein stimulus for 6 h. Representative levels of P2Y4R protein were determined by Western blotting assay. These data are from three
independent experiments. d, e Primary mouse astrocytes were incubated in a serum-free medium overnight followed by pretreating with or
without 50 μM PD98059 for 2 h, prior to soluble Tat protein stimulus for 6 h. d Relative mRNA and e release levels of TNFα, IL-6, IP-10, and MCP-
1were measured by qPCR assay and Cytometric Bead Array, respectively. The data are from three independent experiments. The relative
expression levels of genes were normalized to the expression of mouse Actin. *P < 0.05, **P < 0.01, and ***P < 0.001. f, g Primary mouse astrocytes
were incubated in a serum-free medium overnight followed by pretreating with or without 10 μM LY294002 for 2 h, prior to soluble Tat protein
stimulus for 6 h. f Relative mRNA and g release levels of TNFα, IL-6, IP-10, and MCP-1were measured by qPCR assay and Cytometric Bead Array,
respectively. These data are from three independent experiments. The relative expression levels of genes were normalized to the expression of
mouse Actin. The data are represented as the mean ± S.E.M. *P < 0.05, **P < 0.01, and ***P < 0.001
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Inhibition of PI3K/Akt and ERK MAPK pathways
suppresses Tat-mediated P2Y4R expression and
inflammatory response in the primary mouse astrocytes
To further investigate potential molecular mechanisms
by which Tat induces P2Y4R expression, we analyzed the
phosphorylation levels of Akt and ERK1/2 in synchro-
nized astrocytes stimulated with Tat protein at different
time point. Phosphorylated Akt (p-Akt) was increased
by 2.73 times, 4.21 times, 7.46 times, 5.33 times, 3.17
times, and 2.52 times in astrocytes treated with Tat at
2 min, 5 min, 10 min, 20 min, and 30 min, respectively
(Fig. 2a). Similarly, the phosphorylation level of ERK1/2
(p-ERK1/2) was risen by 3.43 times, 4.67 times, 5.11
times, 4.38 times, 2.41 times, and 3.54 times in astro-
cytes treated with Tat at 2 min, 5 min, 10 min, 20 min,
and 30 min, respectively (Fig. 2a). The data indicate that
Tat activates Akt and ERK1/2 signal pathways.
Then, we assessed whether Akt and ERK1/2 signal
pathways were essential in P2Y4R expression induction
by Tat. The PI3K/Akt pathway inhibitor LY294002 and
ERK1/2 inhibitor PD98059 were applied to primary
mouse astrocytes, followed by Tat. Inhibition of both
PI3K/Akt and ERK1/2 pathways reduced significantly
P2Y4R protein expression (Fig. 2b, c). Thus, Tat triggers
PI3K/Akt and ERK1/2 signal pathways to promote
P2Y4R expression in astrocytes.
To investigate whether PI3K/Akt and ERK MAPK sig-
nals is also required for inflammatory cytokine produc-
tion during Tat challenges, the levels of TNFα, IL-6,
IP-10, and monocyte chemoattractant protein-1
(MCP-1) were monitored. Both PD98059 and LY294002
dramatically reduced mRNA level of Tnfα, Il-6, IP-10,
and Mcp-1 as determined by qPCR in in primary mouse
astrocytes stimulated by Tat (Fig. 2d, f ). The protein
levels of TNFα, IL-6, IP-10, and MCP-1 were also sig-
nificantly diminished in astrocytes after pretreated by
PD98059 and LY294002 (Fig. 2e, g).
P2Y4R signaling regulates inflammatory response in
mouse astrocytes by Tat
To ascertain whether P2Y4R signal was involved in
regulating Tat-induced inflammatory responses, P2Y 4R
Fig. 3 P2Y4R signaling regulates inflammatory response and ATP production in mouse astrocytes by Tat. a Primary mouse astrocytes were incubated
in a serum-free medium overnight followed by pretreating with or without 100 μM ATP for 2 h, prior to soluble Tat protein stimulus for 6 h. Relative
release levels of TNFα, IL-6, and MCP-1were determined by cytometric bead array. These data are from three independent experiments. Error bars
represent the mean ± S.E.M. *P < 0.05, **P < 0.01, and ***P < 0.001. b, c Determination of sh-RNA knockdown of P2Y4R were performed by Western
blotting assay in primary mouse astrocytes transduced with sh-Ctrl and sh-P2Y4R1/2/3 for 72 h, respectively. **P < 0.01 versus NC. d P2Y4R protein was
measured by immunoblotting assay, and relative protein levels of TNFα, IL-6, and MCP-1 were determined by cytometric bead array (n = 3). The data
are represented as the mean ± S.E.M. *P < 0.05 and **P < 0.01. e Relative ATP levels were analyzed by the ATPlite luminescence assay system. The data
are from three independent experiments. The data are represented as the mean ± S.E.M. **P < 0.05 and ***P < 0.01
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agonist ATP was applied to primary mouse astrocytes
together with or without soluble Tat protein. As shown
in Fig. 3a, ATP significantly enhanced the effect of
Tat-induced TNFα, IL-6, and MCP-1 expression. To fur-
ther demonstrate the role P2Y4R in Tat-mediated in-
flammation, P2Y4R expression was knockdown by
shRNA. Sh-P2Y4R-3 significantly suppressed P2Y4R ex-
pression (Fig. 3b, c). We then treated the primary mouse
astrocytes that had transduced by sh-P2Y4R-3 or sh-Ctrl
with Tat for 24 h; the secretion of TNFα, IL-6, and
MCP-1 was measured by Cytometric Bead Array. Immi-
noblot assay confirmed that P2Y4R knockdown inhibited
Tat-induced P2Y4R protein, and importantly P2Y4R
knockdown decreased the release of TNFα, IL-6, and
MCP-1 significantly (Fig. 3d). Overall, these data confirm
that P2Y4R signaling participates in Tat-induced proin-
flammatory cytokine production.
P2Y4R inhibition decreases the release of ATP in mouse
astrocytes by Tat
To determine how Tat engages P2YR signals, ATP pro-
duction were measured using the ATPlite luminescence
assay system. The results indicated that ATP release was
dramatically increased in astrocytes treated with Tat, and
interestingly, it also significantly reduced in P2Y4R-3-
knockdowned cells (Fig. 3e).
Tat upregulates P2Y4R signaling to mediate inflammatory
process and ATP release in human glioma cells via PI3K/
Akt and ERK pathways
To determine whether the Tat-induced P2Y4R pathway
also works in human astrocyte, human glioma U251
cells were pretreated with or without PD98059 and
LY294002 for 2 h, followed by soluble Tat stimulus for
another 6 h, and PRY4R protein expression was then de-
termined by immunoblot assay; the mRNA levels of
TNFα, IL-6, MCP-1, and ATP were detected by qPCR
and ATPlite luminescence assay, respectively. Western
blotting results indicated that P2Y4R expression was sig-
nificantly enhanced by Tat, and was reduced by
PD98059 or LY294002 (Fig. 4a). Tat-induced TNFα, IL-6,
and MCP-1 mRNA expression were dramatically sup-
pressed by PD98059 and LY294002 (Fig. 4b). ATPlite lu-
minescence assay showed that ATP levels were
increased by Tat, and was decreased upon treatment
with PD98059 or LY294002 (Fig. 4c). These data indicate
that soluble Tat enhances P2Y4R signaling in human as-
trocytes via PI3K/Akt and ERK pathways.
Fig. 4 Tat upregulates P2Y4R signaling to produce inflammatory cytokines and ATP release in human glioma cells via PI3K/AKT and ERK pathways.
Human glioma U251 cells were pretreated with or without PD98059 and LY294002 for 2 h, followed by soluble Tat stimulus for 6 h. a PRY4R protein
expression was determined by Western blotting assay. b The mRNA levels of TNFα, IL-6, MCP-1 were detected using qPCR. The relative expression
levels of genes were normalized to the expression of human Actin. c ATP was detected using ATPlite luminescence assay system. The Data are from
three independent experiments. The data are represented as the mean ± S.E.M. **P < 0.05 and ***P < 0.01 versus NC with DMSO; #P < 0.05, ##P < 0.01
and ###P < 0.001 versus Tat with DMSO
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P2Y4R knockdown displays neuroprotective effect against
Tat
Previous data have documented that P2 receptors are asso-
ciated with the growth and survival of neurons in the CNS
[53]. To explore whether P2Y4R signal protected neuron
injury against Tat, primary mouse astrocytes were trans-
duced by LV-sh-P2Y4R-3 or LV-sh-Ctrl for 72 h, followed
by Tat stimulus for 24 h, and then cell culture supernatants
were collected as astrocyte-derived conditioned media
(ACM). The ACM was applied to HT-22 cell, an immortal-
ized mouse hippocampal cell. The apoptotic cell death and
cell survival were determined by TUNEL staining and
MTT cell viability assay, respectively. TUNEL staining
showed that a large number of apoptotic cells were ob-
served in LV-sh-Ctrl-treated group, but which was reversed
in LV-sh-P2Y4R-treated group (Fig. 5a, b). Cell viability was
decreased in the ACM derived from LV-sh-Ctrl-transduced
astrocytes, which was rescued in the ACM from
LV-sh-P2Y4R-tranduced astrocytes (Fig. 5c).
Knockdown of P2Y4R represses inflammation and neuron
death of hippocampal CA1 region in Tat-treated mice
To further verify the role of P2Y4R in Tat-induced in-
flammatory process and neuron injury in vivo, IFA was
performed to detect whether Tat induce P2Y4R protein
level in astrocytes in the brain. As shown in Fig. 6a, b,
Tat upregulated the expression of P2Y4R protein in as-
trocytes. Then, we assessed the effect of P2Y4R blockade
by systemic administration of LV-sh-P2Y4R and
LV-sh-Ctrl on mice (Fig. 6c). As shown in Fig. 6d, Tat in-
creased P2Y4R protein expression in hippocampal re-
gion, but it was suppressed by LV-sh-P2Y4R. The
mRNA levels of Tnfα, Il-6, IP-10, and Mcp-1 were in-
creased in the hippocampal tissues from Tat-injected
mice, and were decreased by LV-sh-P2Y4R compared
with LV-sh-Ctrl (Fig. 6e). Apoptotic cells of hippocampal
neuron were measured by TUNEL staining and cresyl
violet staining, respectively. As shown in Fig. 6f, g, com-
pared with the PBS group, numbers of TUNEL-positive
cells were significantly increased in the Tat-treated
group. Administration of LV-sh-P2Y4R before Tat injec-
tion significantly reduced TUNEL-positive cells, compar-
ing with the LV-sh-Ctrl group. Cresyl violet staining
displayed that normal CA1 neuronal cells showed round
and palely stained nuclei, whereas Tat-induced dead cells
showed pyknotic nuclei (Fig. 6h). Administration of
LV-sh-P2Y4R significantly decreased neuronal degener-
ation, compared with LV-sh-Ctrl group (Fig. 6h). Mean-
time, the neuronal density was dramatically decreased in
Tat-treated mice, compared to PBS group; which was
Fig. 5 P2Y4R knockdown signaling displays neuroprotective effects against Tat. a Primary mouse astrocytes were transduced with sh-Ctrl and
sh-P2Y4R3 for 48 h, followed by Tat stimulus for 24 h. Cell supernatants were collected as astrocyte-derived conditioned media (ACM) and added
into HT-22 cells to incubate for 24 h. Representative apoptotic cells were determined by TUNEL staining in HT-22 cells through incubating in
ACM for 24 h. Red color as apoptosis positive; blue color of DAPI as nucleus location. b Quantification of apoptosis positive cells a was calculated
through answering for percent of total DAPI positive cells. The data are from three independent experiments. The data are represented as the
mean ± S.E.M. *P < 0.05 and **P < 0.01. c Relative cell viability was analyzed by MTT assay in HT-22 cells treated with CAM for 24 h and
48 h (n = 5). The experiment was independently repeated three times. The data are represented as the mean ± S.E.M. *P < 0.05 and **P < 0.01 versus
NC with sh-Ctrl; #P < 0.05 and ##P < 0.01 versus Tat with sh-P2Y4R3
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increased in LV-sh-P2Y4Rgroup, comparing with
LV-sh-Ctrl group (Fig. 6i). Taken together, these results
represent that inhibition of P2Y4R protects neuron
death against Tat.
Discussion
A large body of evidence has demonstrated that purinergic
P2 receptors play an important role in neuroinflammatory
diseases such as Alzheimer’s and Parkinson’s diseases [53,
54]. Growing evidence shows that that P2X7 receptor acti-
vation induces large-scale ATP release. ATP acting via
P2X7 receptor is the second signal to the inflammasome
activation, inducing both maturation and release of
pro-inflammatory cytokines, such as IL-1β and IL-18, and
the production of reactive nitrogen and oxygen species.
Furthermore, the P2X7 receptor is involved in caspases
Fig. 6 Knockdown of P2Y4R represses inflammation and neuron death of hippocampal CA region in Tat-injected mice. a IFA was performed to test
GFAP and P2Y4R protein levels in the brain tissue from Tat-treated mice. b Calculating the percent of P2YR4 expression in GFAP positive cells. The
data are represented as the mean ± S.E.M. *P < 0.05. c Schematic diagram of experimental design in mice. Mice were subjected to LV-sh-Ctrl and LV-sh-
P2Y4R3 for 14 days before Tat injection, respectively (n = 12 mice/group). d Representative P2Y4R protein expression was analyzed by Western blotting
in hippocampal tissues (n = 6). e Relative mRNA expression of TNFα, IL-6, MCP-1, and IP-10 was measured using qPCR assay (n = 6). The relative
expression levels of genes were normalized to the expression of mouse Actin. The data are represented as the mean ± S.E.M. *P < 0.05, **P < 0.01 and
***P < 0.001. f Representative neuronal apoptosis in hippocampal CA1 subfield photomicrographs was TUNEL staining and counterstaining with
methyl green (n = 5). Original magnification, × 400. g Quantification of the percent of apoptosis positive neurons. Data were obtained from five
independent animals and represented as the mean ± S.E.M. *P < 0.05 versus NC with LV-sh-Ctrl; #P < 0.05 versus Tat with LV-sh-P2Y4R3. h
Representative cresyl violet-stained sections of the hippocampal tissues. Original magnification, × 400. i Quantification of hippocampal CA1
neuron density. Data were obtained from five independent animals and represented as the mean ± S.E.M. **P < 0.01 versus NC with LV-sh-
Ctrl; #P < 0.05 versus Tat with LV-sh-P2Y4R3
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activation, as well as in apoptosis induction [55]. Previous
studies reported that Tat enhanced P2X7R expression to
mediate neuroinflammation and neuronal damage [56].
However, few studies reported purinergic P2Y receptors
on regulating inflammatory process and neuron injury in
HAND. In the present study, we aimed to explore the role
of purinergic P2Y receptors in regulating astrocytes func-
tions and HAND pathogenesis. Here, we illustrated the ef-
fects of P2Y4R on the production of inflammatory
cytokines in astrocytes with Tat treatment and neuron
death (Fig. 7). Tat augmented P2Y4R expression through
activated PI3K/Akt and ERK MAPK pathways to promote
production of inflammatory cytokines and ATP. Notably,
P2Y4R knockdown reduced inflammation and alleviated
hippocampal neuron impairment in Tat-injected mice.
Numerous studies have determined that Tat is a vital
neurotoxic mediator [30, 57]. Previous studies exhibited
that soluble Tat protein triggers the production of proin-
flammatory chemokines like IL-8, IP-10, and MCP-1 [8,
25, 56, 57], as well as cytokines including IL-1β, IL-6,
and TNF-α in astrocytes [26, 56]. Tat leads to endoplas-
mic reticulum (ER) stress in astrocytes, which in turn
contributes to astrocyte-mediated Tat neurotoxicity [58].
In addition, Tat regulates excitatory amino acids and
ATP, resulting in neuron cell death [28, 29]. However,
the mechanism by which Tat promotes the production
of inflammatory cytokines and ATP in astrocytes and
HAND pathogenesis was not completely understood.
PI3K/Akt and ERK MAPK pathways play vital roles in
cell growth and differentiation, metabolism, inflammation,
and neurodegenerative diseases. In CNS, PI3K/Akt and
ERK pathways are activated by ATP or UTP to regulate
P2Y4R expression in astrocytes [41, 43]. Furthermore, ac-
tivation of P2Y4R signaling can promote proinflammatory
cytokines production and ATP release [59], in turn trig-
gers calcium overload to exacerbate neuron apoptosis and
dysfunction [31, 32, 60]. Here, we demonstrated that the
expression of P2Y4R was significantly increased in astro-
cytes treated with soluble Tat, and suppressed by inhib-
ition of PI3K/Akt and ERK pathways. Meanwhile, Tat
increased ATP level via PI3K/Akt and ERK pathways. Of
importance, extracellular ATP enhanced Tat-induced pro-
duction of inflammatory cytokines and chemokines, indi-
cating ATP promoting the productions of inflammatory
cytokines through upregulating PI3K/Akt and ERK signals
in astrocytes. We also found that reduction of P2Y4R ex-
pression by LV-shRNA significantly downregulated in-
flammatory cytokine expression in hippocampal tissues
from Tat-injected mice. It was shown that modulating
P2Y4R expression and PI3K/Akt and ERK signal activa-
tion would be a potential target for drug development
aimed to control neuroinflammation and several types of
inflammatory diseases [25, 38, 41, 59].
Inflammation of the CNS is a typical feature of neuro-
logical disorders that are characterized by activation of
glial cells. In present study, we evaluated that 100 ng/ml
of soluble Tat protein significantly triggered inflammatory
cytokine production in astrocytes, and administration of
1 μg Tat protein through i.c.v. infusion elicited inflamma-
tory response in mice, which was decreased by P2Y4R
knockdown. Notably, P2Y4R knockdown attenuated neur-
onal apoptosis and death through activated astrocytes by
Tat in vitro, protected neuronal apoptosis against Tat, and
restored hippocampal CA1 neuron density in vivo.
Conclusion
Taken together, our data demonstrated that the upregu-
lation of P2Y4R signal both in mice and in activated
Fig. 7 Schematic diagram of P2Y4R signal activated by Tat via PI3K/Akt and ERK pathways in astrocyte-mediated neuron death. Under soluble Tat
stimulation, P2Y4R are upregulated in astrocytes via PI3K/Akt and ERK pathways, which increases inflammatory process and ATP release to
damage neuron, thus exacerbating the HAND process
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human astrocytes by Tat regulates the production of
inflammatory cytokines and chemokines as well as
ATP in astrocytes and in mice via triggering the
PI3K/Akt and ERK pathways, which is responsible for
HAND process. Thus, our findings on the underlying
mechanisms that regulate astrocyte function and the
HAND pathophysiological process broaden horizons
in understanding of HAND pathophysiology and po-
tential therapeutic strategies.
Additional file
Additional file 1: Figure S1. Distribution of GFP in CNS of mice infected
by lentivirus. The lentivirus suspension of LV-sh-P2Y4R was injected into
mice through the tail vein for 14 days, and then mice were sacrificed and
frozen sections (15 μm) from brain tissues. GFP expression was
detected under fluorescence microscope (n = 3, original amplification,
× 40). Table S1. The list of primer sequences for qPCR assay. (ZIP 263 kb)
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